Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Goodwill (2017 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Goodwill for 9 consecutive years, with $44.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Goodwill changed 0.0% to $44.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $44.0 million, a 0.0% change, with the full-year FY2025 number at $44.0 million, changed 0.0% from a year prior.
  • Goodwill was $44.0 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $44.4 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $44.4 million in Q1 2021 to a low of $44.0 million in Q4 2024.
  • A 5-year average of $44.4 million and a median of $44.4 million in 2021 define the central range for Goodwill.
  • Peak YoY movement for Goodwill: changed 0.0% in 2021, then decreased 0.91% in 2024.
  • Ultragenyx Pharmaceutical's Goodwill stood at $44.4 million in 2021, then changed by 0.0% to $44.4 million in 2022, then changed by 0.0% to $44.4 million in 2023, then fell by 0.91% to $44.0 million in 2024, then changed by 0.0% to $44.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Goodwill are $44.0 million (Q4 2025), $44.4 million (Q3 2025), and $44.4 million (Q2 2025).